about
The role of host factors and bacterial virulence genes in the development of pyelonephritis caused by Escherichia coli in renal transplant recipients.Phyllanthus niruri as a promising alternative treatment for nephrolithiasis.Stop dietary calcium restriction in kidney stone-forming patients.Overweight and body fat are predictors of hypovitaminosis D in renal transplant patients.Selective estrogen receptor modulators in chronic renal failure.Response to dietary oxalate after bariatric surgery.Bone disease in idiopathic hypercalciuria.Renal stone disease: Causes, evaluation and medical treatment.Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C.Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.Optimum nutrition for kidney stone disease.Urolithiasis and pregnancy.Phosphate and FGF-23 homeostasis after kidney transplantation.Treatment of patients with uric acid stones.Bone turnover after bariatric surgery.N-acetylcysteine protects against star fruit-induced acute kidney injury.Costs for in hospital treatment of urinary lithiasis in the Brazilian public health system.Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease.Adult presentation of Bartter syndrome type IV with erythrocytosis.Translation, cultural adaptation and aplication of a pain questionnaire for patients with polycystic kidney disease.Effects of an oxalate load on urinary oxalate excretion in calcium stone formers.Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients.An approximate estimate of the ion-activity product of calcium oxalate in rat urine.Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion.The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers.Effects of calcium supplementation on body weight reduction in overweight calcium stone formers.Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.Pain determinants of pain in autosomal dominant polycystic kidney disease.Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry.Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease.Kidneys and women's health: key challenges and considerations.Whey protein and albumin effects upon urinary risk factors for stone formation.Simplified estimates of ion-activity products of calcium oxalate and calcium phosphate in mouse urine.Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formersBartter syndrome: causes, diagnosis, and treatmentAssociation of Vitamin D Levels With Kidney Volume in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
P50
Q33944841-99E8DB4C-8FFD-4628-807D-51E167768982Q34156072-85330704-AEE0-42FF-94A0-F96167F9953FQ34764567-03CDBE49-CC60-4841-A3F8-F50688A05A74Q35026465-E4A8E06B-076D-4623-816A-14D0CF63C243Q35129886-C5D53991-F795-44C1-A2A1-80D7D87068BBQ36443214-2ACFD82D-1F1B-466D-9946-BE0154EF68D4Q36507240-0BC3347B-10FD-4CD2-8310-B4E6F37BB814Q36658996-5D8C6DD0-89E2-473B-AAF1-D84C68645894Q36666822-AA6AB6D3-4E28-431C-A70B-477301FB8C06Q37152515-7F06270D-88AD-4426-AE41-20B09842F8F6Q37366264-8AFD71EC-616F-4294-96AE-9EC62C464CE1Q38084518-4C8EC344-9E2F-4C25-BD65-18E8C5492EA0Q38260423-C42E5A45-EAE7-46AB-BB11-E25859D559F9Q38594874-D1512925-4678-4566-AE53-6B3696E5289BQ38662261-311ABD4C-40F7-4408-AB82-7772207AA745Q38671841-75B09F3B-68DA-4852-B810-11A3E1FD7B91Q39186975-0AE8AB5E-C449-4A85-9A5A-FC8285F982EEQ40113881-0F981A68-8C0A-4C09-B932-F3D2D88D5BE6Q41728196-0E2ABA85-B095-4648-BFBC-EE105CA1D710Q41839151-DDAD2978-C357-428C-B8D6-EF0579A94386Q43723459-5741CC61-6935-48A4-AFC6-47628573ACF9Q44300613-F395E84A-5426-423D-B691-FB3A8B182DBDQ44358487-6AD8B730-B333-4EAF-9873-72F499F71588Q44632460-58722B27-01B7-4A8D-BAEA-4E32F9B948DCQ44978358-6B25314D-27A7-4B0B-917A-6331828B1A66Q45352827-B66BB39F-9A5F-4605-AB28-DE726992DCC9Q46072255-4E144DEF-3CEF-44B9-B740-A038BA5CD9E7Q46418934-5958BC26-E671-471B-BCAE-9B661EEB64B4Q46837373-5F3161A2-12F1-49E0-953B-74C06B8C588BQ46839976-A3DCE09F-362A-42C3-85D4-805A154111E5Q48623828-E5012AAE-832B-4794-977D-4BE3DD2CE1B4Q49584076-D1EF787D-B235-4525-A773-25857F84BAB6Q51090228-56D5642C-97DB-44B8-8A94-D55ADEDDA580Q51463857-A4AE3981-4406-4C1D-9E61-23F4E384628BQ58588756-41C18BA3-353A-47FF-A69F-F73B76C83222Q59793755-1709BE0E-90FA-482B-8EE0-5905AEBCDFACQ64947165-FAA23EE8-386A-48B1-B20F-F6C944ADA769
P50
name
Ita Pfeferman Heilberg
@ast
Ita Pfeferman Heilberg
@en
Ita Pfeferman Heilberg
@nl
type
label
Ita Pfeferman Heilberg
@ast
Ita Pfeferman Heilberg
@en
Ita Pfeferman Heilberg
@nl
prefLabel
Ita Pfeferman Heilberg
@ast
Ita Pfeferman Heilberg
@en
Ita Pfeferman Heilberg
@nl